Markets:

Overview

News

Currencies

International

Treasuries

RenovoRx, Inc. - Common Stock (NQ:RNXT)

0.9806 -0.0494 (-4.80%)

Streaming Delayed Price Updated: 9:30 AM EDT, Apr 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about RenovoRx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Top movers in Monday's pre-market session ↗

January 12, 2026

Via Chartmill

The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech

January 08, 2026

From Equity Insider

Via GlobeNewswire

Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025

December 08, 2025

Via ACCESS Newswire

Earnings Scheduled For November 13, 2025 ↗

November 13, 2025

Via Benzinga

Earnings Scheduled For August 14, 2025 ↗

August 14, 2025

Via Benzinga

Earnings Preview For RenovoRx ↗

May 14, 2025

Via Benzinga

iAccess Alpha's Virtual Best Ideas Winter Investment Conference December 9-10, 2025

December 01, 2025

Via ACCESS Newswire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

November 14, 2025

Via Benzinga

RENOVORX INC (NASDAQ:RNXT) Reports Significant Q3 2025 Revenue Miss and 5% Stock Drop ↗

November 13, 2025

RenovoRx Q3 2025 earnings show a 35% revenue miss, causing a stock drop. The clinical-stage biopharma provided a 2026 growth outlook to offset cash burn.

Via Chartmill

RenovoRx (RNXT) Q3 2025 Earnings Call Transcript ↗

November 13, 2025

RenovoRx (RNXT) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings Economy

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 10, 2025

Via Benzinga

Updated Lineup Announced for iAccess Alpha's Virtual Best Ideas Fall Investment Conference September 16-17, 2025

September 16, 2025

Via ACCESS Newswire

iAccess Alpha's Virtual Best Ideas Fall Investment Conference September 16-17, 2025

September 09, 2025

Via ACCESS Newswire

Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge ↗

September 08, 2025

Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga's Edge Stock Rankings.

Via Benzinga

Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗

September 03, 2025

As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright’s 27th Annual Global Investment Conference in New York City, September 8-10, 2025

August 20, 2025

From RenovoRx, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

August 15, 2025

Via Benzinga

Gapping stocks in Friday's session ↗

August 15, 2025

The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.

Via Chartmill

What's going on in today's pre-market session ↗

August 15, 2025

Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session.

Via Chartmill

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

August 15, 2025

Via Benzinga

RenovoRx Revenue Jumps 28 Percent in Q2 ↗

August 14, 2025

Via The Motley Fool

Topics Intellectual Property

RenovoRx Inc. (NASDAQ:RNXT) Q2 2025 Earnings: Revenue Surpasses Estimates, Shares Climb on Positive Results ↗

August 14, 2025

RenovoRx (NASDAQ:RNXT) Q2 2025 revenue beats estimates at $422K, shares rise 4.8%. RenovoCath adoption grows, Phase III trial progresses. Strong cash position supports operations.

Via Chartmill

RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review

August 14, 2025

From RenovoRx, Inc.

Via Business Wire

RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors

July 28, 2025

From RenovoRx, Inc.

Via Business Wire

RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET

July 14, 2025

From RenovoRx, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

June 27, 2025

Via Benzinga

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

May 15, 2025

From RenovoRx, Inc.

Via Business Wire

Earnings Scheduled For May 15, 2025 ↗

May 15, 2025

Via Benzinga

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

May 14, 2025

From RenovoRx, Inc.

Via Business Wire

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

May 06, 2025

From RenovoRx, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.